Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and Germany. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab; and antibody collaboration with Regeneron Pharmaceuticals, Inc. to develop antibodies, such as Dupixent (dupilumab) as treatment for diseases driven by type 2 inflammation. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.…
European Equities Traded in the US as American Depositary Receipts Track Lower in Friday Trading; Down More Than 7% for Week
Sanofi (NASDAQ: SNY) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 74,846 employees.
The shares were at 46.52 USD on 20 November 2026, down 5.0% over 52 weeks. Its 52-week range is 39.07 USD to 52.68 USD: the price is 11.7% below the high and 19.1% above the low.
At a market capitalisation of 111.70B USD, it trades at 23.1 times trailing earnings and 8.6 times forward earnings. The median trailing P/E of its 18 largest Drug Manufacturers - General peers is 26.1, a discount of 11% for SNY. It pays a dividend yielding 5.25% (it pays out 120% of its earnings), against a median of 2.45% among the dividend payers in that peer group.
Sanofi reports return on equity of 10.9%, an operating margin of 22.3% and revenue up 15.7% year over year.
Its debt exceeds its cash by 13.88B EUR, a debt-to-equity ratio of 0.28. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 9 analysts cover the stock, with an average rating of Buy; their mean price target of 54.92 USD is 18.1% above the current price. The next earnings report is expected on 28 January 2027.